Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMIT: Obinutuzumab vs Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy
NCT06120673Phase 3Withdrawn
- Sponsor
- The University of Queensland
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in primary membranous nephropathy (PMN), sponsored by The University of Queensland. Planned start Oct 2025; status: withdrawn.
02
Drugs
obinutuzumab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06120673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120673.